TACC2

Summary

TACC2 (transforming acidic coiled-coil containing protein 2, HGNC:11523) is a protein-coding gene on chromosome 10q26.13, encoding Transforming acidic coiled-coil-containing protein 2 (O95359). Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome.

Transforming acidic coiled-coil proteins are a conserved family of centrosome- and microtubule-interacting proteins that are implicated in cancer. This gene encodes a protein that concentrates at centrosomes throughout the cell cycle. This gene lies within a chromosomal region associated with tumorigenesis. Expression of this gene is induced by erythropoietin and is thought to affect the progression of breast tumors. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 10579 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 538 total — 1 pathogenic
• MANE Select transcript: NM_206862

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11523
Approved symbol	TACC2
Name	transforming acidic coiled-coil containing protein 2
Location	10q26.13
Locus type	gene with protein product
Status	Approved
Aliases	AZU-1, ECTACC
Ensembl gene	ENSG00000138162
Ensembl biotype	protein_coding
OMIM	605302
Entrez	10579

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 25 protein_coding, 6 retained_intron, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000260733, ENST00000334433, ENST00000358010, ENST00000360561, ENST00000368997, ENST00000368999, ENST00000369000, ENST00000369001, ENST00000369004, ENST00000369005, ENST00000440764, ENST00000453444, ENST00000465600, ENST00000474014, ENST00000489754, ENST00000490979, ENST00000491540, ENST00000492237, ENST00000492689, ENST00000493951, ENST00000496913, ENST00000498721, ENST00000503769, ENST00000505639, ENST00000508411, ENST00000513429, ENST00000514539, ENST00000515273, ENST00000515603, ENST00000635597, ENST00000866908, ENST00000866909, ENST00000866910, ENST00000866911, ENST00000866912

RefSeq mRNA: 8 — MANE Select: NM_206862 NM_001291876, NM_001291877, NM_001291878, NM_001291879, NM_006997, NM_206860, NM_206861, NM_206862

CCDS: CCDS7625, CCDS7626, CCDS7627, CCDS7628, CCDS76348, CCDS76349, CCDS76351, CCDS76352

Canonical transcript exons

ENST00000369005 — 23 exons

Exon	Start	End
ENSE00000933490	122229346	122229486
ENSE00000933491	122230351	122230440
ENSE00001448580	122253991	122254542
ENSE00001745579	122088478	122088591
ENSE00001803587	122082647	122087959
ENSE00003461495	122143572	122143706
ENSE00003484550	122227837	122228008
ENSE00003484960	122021937	122022014
ENSE00003495364	122226366	122226481
ENSE00003496305	122195040	122195176
ENSE00003527935	122132609	122132734
ENSE00003533140	122241958	122242001
ENSE00003558460	122216627	122216828
ENSE00003581496	122237961	122238037
ENSE00003596113	122215391	122215451
ENSE00003608201	122249544	122249664
ENSE00003608463	122249050	122249156
ENSE00003620652	122237395	122237538
ENSE00003663277	122224726	122224787
ENSE00003684619	122248643	122248803
ENSE00003688439	122050438	122050550
ENSE00003689066	122210397	122211708
ENSE00003845911	121989163	121989488

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 99.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.5571 / max 362.7410, expressed in 1487 samples.

FANTOM5 promoters (29 alternative TSS)

Promoter ID	TPM avg	Samples expressed
107414	5.2929	1350
107419	1.7040	305
107412	1.6926	872
107421	1.4626	261
107411	1.1368	583
107396	0.6917	71
107418	0.5581	253
107402	0.4626	125
107395	0.4129	70
107417	0.4004	58

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.05	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.83	gold quality
gastrocnemius	UBERON:0001388	98.74	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.60	gold quality
biceps brachii	UBERON:0001507	98.58	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.58	gold quality
skin of leg	UBERON:0001511	98.48	gold quality
skin of abdomen	UBERON:0001416	98.46	gold quality
right atrium auricular region	UBERON:0006631	98.40	gold quality
muscle of leg	UBERON:0001383	98.39	gold quality
gluteal muscle	UBERON:0002000	98.38	gold quality
body of tongue	UBERON:0011876	98.38	gold quality
skeletal muscle tissue	UBERON:0001134	98.34	gold quality
cardiac atrium	UBERON:0002081	98.22	gold quality
zone of skin	UBERON:0000014	98.21	gold quality
heart left ventricle	UBERON:0002084	98.07	gold quality
cardiac ventricle	UBERON:0002082	98.06	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.79	gold quality
right uterine tube	UBERON:0001302	97.77	gold quality
muscle organ	UBERON:0001630	97.75	gold quality
skeletal muscle organ	UBERON:0014892	97.75	gold quality
palpebral conjunctiva	UBERON:0001812	97.73	gold quality
lower esophagus mucosa	UBERON:0035834	97.57	gold quality
heart	UBERON:0000948	97.51	gold quality
bronchial epithelial cell	CL:0002328	97.50	gold quality
deltoid	UBERON:0001476	97.50	gold quality
heart right ventricle	UBERON:0002080	97.39	gold quality
muscle tissue	UBERON:0002385	97.28	gold quality
lower esophagus	UBERON:0013473	97.21	gold quality
left lobe of thyroid gland	UBERON:0001120	97.20	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7249	yes	11.14
E-MTAB-7303	no	497.15
E-GEOD-124858	no	165.22
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR

miRNA regulators (miRDB)

77 targeting TACC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4671-3P	99.88	72.46	1045
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-199A-3P	99.75	70.48	929
HSA-MIR-199B-3P	99.75	70.48	929
HSA-MIR-3129-5P	99.75	70.46	914

Literature-anchored findings (GeneRIF, showing 14)

• Defects in TACC2 expression may affect gene regulation, thus contributing to the pathogenesis of some tumors. (PMID:12620397)
• GCN5L2 is a TACC2-binding protein. (PMID:14767476)
• Centrosomal TACC2 is required for mitotic spindle maintenance. (PMID:15304323)
• Simian virus 40 large T antigen interacting with TACC2 is involved in stabilizing microtubules in mitosis. (PMID:19671663)
• TACC2 may mediate an oncogenic effect on breast cancer cells. (PMID:20335520)
• Results revealed 3 genes highly predictive of event-free survival (EFS), beyond age and MLL status: FLT3, IRX2, and TACC2. (PMID:22210879)
• Data suggest that TACC2 is highly expressed in prostate cancer cells and contributes to cell cycle progression and cell proliferation in androgen-nonresponsive prostate cancer cells; overexpression of TACC2 leads to recurrence of prostate cancer. (PMID:22456197)
• Differential expression of the transcripts TACC2 connects ubiquitin-proteasome system with infection-inflammation in preterm births and preterm premature rupture of membranes. (PMID:25884766)
• These results suggest that TACC2 plays an important role in the cell proliferation of breast carcinoma and therefore immunohistochemical TACC2 status is a candidate of worse prognostic factor in breast cancer cases. (PMID:27333920)
• TACC2 protein is expressed mainly in the nucleus of the endometrial cancer cells. (PMID:29074988)
• This finding suggests that TACC2 may be a useful tool as a candidate biomarker to predict the recurrence and prognosis of hepatocellular carcinoma. (PMID:29843208)
• Cigarette smoke exposure enhances transforming acidic coiled-coil-containing protein 2 turnover and thereby promotes emphysema. (PMID:31996486)
• Nanopore sequencing reveals TACC2 locus complexity and diversity of isoforms transcribed from an intronic promoter. (PMID:33931666)
• A genome-wide association study identifies a locus associated with knee extension strength in older Japanese individuals. (PMID:38769351)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000062790
mus_musculus	Tacc2	ENSMUSG00000030852
rattus_norvegicus	Tacc2	ENSRNOG00000020457
drosophila_melanogaster	tacc	FBGN0026620

Paralogs (2): TACC3 (ENSG00000013810), TACC1 (ENSG00000147526)

Protein

Protein identifiers

Transforming acidic coiled-coil-containing protein 2 — O95359 (reviewed: O95359)

Alternative names: Anti-Zuai-1

All UniProt accessions (14): A0A0U1RRM9, O95359, D6RAA5, E7EMZ9, E9PBC6, E9PGB3, H0Y8P9, H0Y911, H0Y954, H0Y9C3, H0Y9Y7, H0YA73, Q4VXL4, Q4VXL8

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors. May play a role in organizing centrosomal microtubules. May act as a tumor suppressor protein. May represent a tumor progression marker.

Subunit / interactions. Interacts with CCDC100/CEP120. Interacts with microtubules. Interacts with YEATS4, GCN5L2 and PCAF.

Subcellular location. Cytoplasm. Nucleus. Cytoskeleton. Microtubule organizing center. Centrosome.

Tissue specificity. Strongly expressed in heart, skeletal muscle, brain, prostate, thyroid and trachea.

Post-translational modifications. Phosphorylated by TTK; which is required for localization in centrosome.

Similarity. Belongs to the TACC family.

Isoforms (6)

UniProt ID	Names	Canonical?
O95359-4	4, Long, TACC2s	yes
O95359-1	1, Short
O95359-2	2
O95359-3	3, ECTACC
O95359-5	5, TACC21
O95359-6	6

RefSeq proteins (8): NP_001278805, NP_001278806, NP_001278807, NP_001278808, NP_008928, NP_996742, NP_996743, NP_996744* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007707	TACC_C	Domain
IPR039915	TACC	Family

Pfam: PF05010

UniProt features (105 total): modified residue 36, compositionally biased region 21, sequence variant 18, region of interest 16, splice variant 8, sequence conflict 2, coiled-coil region 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for O95359 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (36): 325, 2625, 197, 201, 269, 493, 561, 571, 575, 758, 962, 1025, 1267, 1313, 1562, 2072, 2161, 2226, 2246, 2256 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 267 (showing top): GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, MORF_FLT1, MODULE_45, AREB6_03, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, RACCACAR_AML_Q6, LUCAS_HNF4A_TARGETS_UP, ATGCAGT_MIR217, MORF_ESR1, MORF_RAD51L3, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_FOREBRAIN_DEVELOPMENT, MODULE_66, MODULE_118, ONKEN_UVEAL_MELANOMA_UP

GO Biological Process (4): microtubule cytoskeleton organization (GO:0000226), mitotic spindle organization (GO:0007052), nuclear migration (GO:0007097), cerebral cortex development (GO:0021987)

GO Molecular Function (1): nuclear receptor binding (GO:0016922)

GO Cellular Component (7): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), plasma membrane (GO:0005886), nucleus (GO:0005634), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoskeleton organization	1
microtubule-based process	1
mitotic cell cycle	1
spindle organization	1
microtubule cytoskeleton organization involved in mitosis	1
intracellular transport	1
nucleus localization	1
establishment of organelle localization	1
pallium development	1
anatomical structure development	1
RNA polymerase II-specific DNA-binding transcription factor binding	1
nuclear lumen	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
cytoplasm	1
membrane	1
cell periphery	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1663 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TACC2	CKAP5	Q14008	768
TACC2	FGFR2	P18443	730
TACC2	FGFR1	P11362	651
TACC2	FGFR3	P22607	623
TACC2	TACC3	Q9Y6A5	574
TACC2	YEATS4	O95619	542
TACC2	AURKC	Q9UQB9	520
TACC2	LMOD1	P29536	492
TACC2	PRCP	P42785	475
TACC2	CEP120	Q8N960	471
TACC2	CEP128	Q6ZU80	467
TACC2	H1-10	Q92522	465
TACC2	GYG1	P46976	463
TACC2	AURKA	O14965	462
TACC2	CNTRL	Q7Z7A1	462

IntAct

23 interactions, top by confidence:

A	B	Type	Score
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
Haus4	HAUS5	psi-mi:“MI:0915”(physical association)	0.560
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
KXD1	TRAK2	psi-mi:“MI:0914”(association)	0.530
TACC2	TTK	psi-mi:“MI:0915”(physical association)	0.460
TTK	TACC2	psi-mi:“MI:0403”(colocalization)	0.460
Dlg4	TACC2	psi-mi:“MI:0407”(direct interaction)	0.440
TACC2	FMR1	psi-mi:“MI:0915”(physical association)	0.370
TACC2	FXR1	psi-mi:“MI:0915”(physical association)	0.370
TACC2	SMARCA2	psi-mi:“MI:0915”(physical association)	0.370
MAP4	TUBA1B	psi-mi:“MI:0914”(association)	0.350
TUBA1B	SLAIN2	psi-mi:“MI:0914”(association)	0.350
TUBB4B	TUBA1B	psi-mi:“MI:0914”(association)	0.350
YWHAE	DEPDC5	psi-mi:“MI:0914”(association)	0.350
TACC1	TACC2	psi-mi:“MI:0914”(association)	0.350
PAXX	TACC2	psi-mi:“MI:0914”(association)	0.350
CANX	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
TOMM20	NUDT19	psi-mi:“MI:2364”(proximity)	0.270
RET	NUDT19	psi-mi:“MI:2364”(proximity)	0.270
FTSJ1	TACC2	psi-mi:“MI:0915”(physical association)	0.000
DISC1	TACC2	psi-mi:“MI:0915”(physical association)	0.000
HMG20B	TACC2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (99): TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-RNA), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), TACC2 (Proximity Label-MS), TACC2 (Proximity Label-MS)

ESM2 similar proteins: A0A1B0GUA9, A0JNH1, A2TJV2, A5PJD3, A5YM69, A6QP92, A7YY35, A8MUA0, D3Z1D3, E9Q3S4, E9Q7D5, M0RD54, O02665, O94854, O95359, P43359, P58871, Q0VDD7, Q0VF49, Q12774, Q3KR64, Q4R736, Q5PSV9, Q5QJ38, Q5R5G4, Q5RJL0, Q5SWP3, Q5ZK13, Q69ZZ9, Q6AXX2, Q6AYA8, Q6DIA7, Q6NXZ1, Q6ZRC1, Q711Q0, Q80VY2, Q86TB3, Q8BHB7, Q8BI84, Q8VBT6

Diamond homologs: O75410, O95359, Q6Y685, Q9JJ11, Q9JJG0, Q9PTG8, Q9Y6A5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by Rho GTPases	5	9.5×	4e-03
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	5	9.3×	4e-03
Viral Infection Pathways	5	8.6×	4e-03
Infectious disease	5	6.9×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
microtubule cytoskeleton organization	5	23.3×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

538 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	423
Likely benign	60
Benign	10

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3148924	GRCh37/hg19 10q26.12-26.3(chr10:122331280-135426386)x1	Pathogenic

SpliceAI

6121 predictions. Top by Δscore:

Variant	Effect	Δscore
10:122021935:A:AG	acceptor_gain	1.0000
10:122021936:G:GA	acceptor_gain	1.0000
10:122050430:T:TA	acceptor_gain	1.0000
10:122132606:CA:C	acceptor_loss	1.0000
10:122132607:A:AG	acceptor_gain	1.0000
10:122132607:A:AT	acceptor_loss	1.0000
10:122132608:G:GC	acceptor_gain	1.0000
10:122132608:GTTC:G	acceptor_gain	1.0000
10:122132608:GTTCA:G	acceptor_gain	1.0000
10:122132732:GAG:G	donor_gain	1.0000
10:122132732:GAGG:G	donor_loss	1.0000
10:122132734:GGTA:G	donor_loss	1.0000
10:122195039:GGA:G	acceptor_gain	1.0000
10:122210392:CCCA:C	acceptor_loss	1.0000
10:122210393:CCA:C	acceptor_loss	1.0000
10:122210394:CA:C	acceptor_loss	1.0000
10:122210395:A:AC	acceptor_loss	1.0000
10:122210395:A:AG	acceptor_gain	1.0000
10:122210395:AG:A	acceptor_gain	1.0000
10:122210396:G:GT	acceptor_gain	1.0000
10:122210396:GG:G	acceptor_gain	1.0000
10:122210396:GGAT:G	acceptor_gain	1.0000
10:122211706:GAC:G	donor_gain	1.0000
10:122211709:G:GG	donor_gain	1.0000
10:122216622:TGCA:T	acceptor_loss	1.0000
10:122216623:GCA:G	acceptor_loss	1.0000
10:122216624:CA:C	acceptor_loss	1.0000
10:122216625:A:AC	acceptor_loss	1.0000
10:122216625:A:AG	acceptor_gain	1.0000
10:122216625:AG:A	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000023991 (10:122144670 C>A,T), RS1000023994 (10:122119730 A>G), RS1000029528 (10:122224967 C>A), RS1000059851 (10:122073994 A>G), RS1000060539 (10:122138615 T>C), RS1000075960 (10:122225727 G>A), RS1000080384 (10:122150151 G>C), RS1000101396 (10:122068247 A>G), RS1000112629 (10:122206324 C>A,T), RS1000118300 (10:122144402 A>G), RS1000134550 (10:122074258 T>G), RS1000153667 (10:122162549 T>C), RS1000188990 (10:122219043 G>A), RS1000189850 (10:122054939 G>A), RS1000192046 (10:122133440 T>C)

Disease associations

OMIM: gene MIM:605302 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001712_13	Myopia (pathological)	2.000000e-07
GCST001762_63	Obesity-related traits	3.000000e-06
GCST003944_31	Hepcidin/ferritin ratio	7.000000e-06
GCST005348_126	Total body bone mineral density	3.000000e-09
GCST005348_201	Total body bone mineral density	4.000000e-11
GCST006171_15	Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)	1.000000e-08
GCST007448_13	Normal facial asymmetry (angle of surface orientation score)	3.000000e-14
GCST007448_4	Normal facial asymmetry (angle of surface orientation score)	2.000000e-12
GCST008424_3	Opioid dependence	1.000000e-07
GCST008424_4	Opioid dependence	2.000000e-07
GCST008424_6	Opioid dependence	3.000000e-07
GCST008869_4	Metabolite risk score for predicting weight gain	3.000000e-08
GCST012155_1	Chronic lymphocytic leukemia (time to first treatment)	3.000000e-09

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004207	pathological myopia
EFO:0007901	hepcidin:ferritin ratio
EFO:0005763	pulse pressure measurement
EFO:0009751	facial asymmetry measurement
EFO:0004566	body weight gain
EFO:0004725	metabolite measurement
EFO:0004920	progression free survival

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

70 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	increases expression, affects expression, decreases expression, decreases methylation	4
Valproic Acid	affects expression, decreases methylation, affects cotreatment, increases expression	3
Acetaminophen	decreases expression, increases expression	2
Vehicle Emissions	decreases methylation, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects methylation, increases methylation	2
Particulate Matter	affects cotreatment, increases abundance, increases expression	2
FR900359	decreases phosphorylation	1
ginger extract	decreases expression, increases abundance	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	decreases expression	1
alpha-pinene	increases expression, increases abundance, affects cotreatment	1
bisphenol A	affects methylation	1
lead acetate	decreases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
decabromobiphenyl ether	decreases expression	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	decreases expression	1
benzo(e)pyrene	increases methylation	1
cupric chloride	decreases expression	1
coumarin	affects phosphorylation	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2I1	Abcam HeLa TACC2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.